Multiple Patents Granted and Pipeline of Ophthalmic Drug Candidates

We are advancing wholly-owned ophthalmic drug pipeline candidates that address a number of diseases with high unmet need, from front-of-eye conditions to back-of-eye conditions. The lead project is CBT-001 for the treatment of pterygium.